Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo and San Francisco, CA – June 3, 2013 – Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced that after a priority review, Health Canada has approved XTANDI®
Tokyo Japan, May 31, 2013 - Nippon Boehringer Ingelheim Co., Ltd. (headquartered in Shinagawa-ku, Tokyo; president, Yoshiaki Aono; hereinafter referred to as “Nippon Boehringer Ingelheim”) and...
THOUSAND OAKS, Calif., and TOKYO (May 29, 2013) – Amgen (NASDAQ:AMGN), the world’s largest independent biotechnology company, and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503,...
Tokyo, May 28, 2012 – Astellas Pharma Inc. (Tokyo:4503) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of...
Follow us
